Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

« Previous Article | Table of Contents | Next Article »

Circulation. 1990;82:774-780

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Download to citation manager
	Request Permissions

Citing Articles

	Citing Articles via HighWire
	Citing Articles via Google Scholar

Google Scholar

	Articles by Uretsky, B. F.
	Articles by Sandberg, J. A.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Uretsky, B. F.
	Articles by Sandberg, J. A.

ARTICLES

Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

BF Uretsky, M Jessup, MA Konstam, GW Dec, CV Leier, J Benotti, S Murali, HC Herrmann and JA Sandberg
Presbyterian-University Hospital, Pittsburgh, PA 15213.

A multicenter double-blind, randomized, placebo-controlled trial of oral enoximone, a phosphodiesterase inhibitor, was conducted in 102 outpatients (50 receiving enoximone and 52 receiving placebo) with moderate to moderately severe congestive heart failure. All were on a long-term regimen of digoxin and diuretics without vasodilators and converting enzyme inhibitors. Symptom score was obtained, and exercise testing was performed monthly for 4 months. There were no differences between groups in symptoms or exercise duration at the end of 4 months. A subgroup undergoing analysis of oxygen consumption with measurement of anaerobic threshold during exercise showed an increase (p less than 0.05) in anaerobic threshold at 1 month with enoximone. (2.7 +/- 0.8 ml O2/kg/min) compared with placebo (-0.8 +/- 1.2 ml O2/kg/min). This improvement was not sustained at 4 months (0.5 +/- 1.7 ml O2/kg/min with enoximone and 0.2 +/- 1.5 ml O2/kg/min with placebo). The dropout rate was significantly higher (p less than 0.02) with enoximone (46%) than with placebo (25%). Adverse effects other than death were slightly, but not significantly, higher with enoximone (32%) than with placebo (22%). During therapy, five deaths occurred in the enoximone group, and none occurred in the placebo group (p less than 0.05). Two deaths were sudden, two were from progressive congestive heart failure, and one was from acute myocardial infarction. With intention-to-treat analysis and inclusion of patients who were removed from therapy because of lack of study drug effect, 10 deaths occurred in the enoximone group, and three occurred in the placebo group (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

M. Metra, E. Eichhorn, W. T. Abraham, J. Linseman, M. Bohm, R. Corbalan, D. DeMets, T. De Marco, U. Elkayam, M. Gerber, et al.
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials
Eur. Heart J., December 2, 2009; 30(24): 3015 - 3026.
[Abstract] [Full Text] [PDF]

J. N. Cohn
Inotropic therapy for heart failure: paradise lost
Eur. Heart J., December 2, 2009; 30(24): 2965 - 2966.
[Full Text] [PDF]

S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90.
[Full Text] [PDF]

M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, M. A. Silver, et al.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1343 - 1382.
[Full Text] [PDF]

2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA, M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, et al.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
Circulation, April 14, 2009; 119(14): 1977 - 2016.
[Full Text] [PDF]

2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
Circulation, April 14, 2009; 119(14): e391 - e479.
[Full Text] [PDF]

C. J.F. Holubarsch, W. S. Colucci, T. Meinertz, W. Gaus, M. Tendera, and Survival and Prognosis: Investigation of Crataegus
The efficacy and safety of Crataegus extract WS(R) 1442 in patients with heart failure: The SPICE trial
Eur J Heart Fail, December 1, 2008; 10(12): 1255 - 1263.
[Abstract] [Full Text] [PDF]

M. Fenton and M. Burch
Understanding chronic heart failure
Arch. Dis. Child., September 1, 2007; 92(9): 812 - 816.
[Abstract] [Full Text] [PDF]

B. Keweloh, P. M.L. Janssen, U. Siegel, N. Datz, O. Zeitz, and H.-P. Hermann
Influence of pyruvate on economy of contraction in isolated rabbit myocardium
Eur J Heart Fail, August 1, 2007; 9(8): 754 - 761.
[Abstract] [Full Text] [PDF]

A. L. Taylor, S. Ziesche, C. W. Yancy, P. Carson, K. Ferdinand, M. Taylor, K. Adams, A. Y. Olukotun, E. Ofili, S. W. Tam, et al.
Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial
Circulation, April 3, 2007; 115(13): 1747 - 1753.
[Abstract] [Full Text] [PDF]

J. G.F. Cleland, A. P. Coletta, M. Lammiman, K. K. Witte, H. Loh, M. Nasir, and A. L. Clark
Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE
Eur J Heart Fail, October 1, 2005; 7(6): 1070 - 1075.
[Abstract] [Full Text] [PDF]

K. Lalukota, J. G.F. Cleland, L. Ingle, A. L. Clark, and A. P. Coletta
Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD
Eur J Heart Fail, December 1, 2004; 6(7): 953 - 955.
[Abstract] [Full Text] [PDF]

J. J. Magner and D. Royston
Heart failure
Br. J. Anaesth., July 1, 2004; 93(1): 74 - 85.
[Abstract] [Full Text] [PDF]

M. A Movsesian
Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy
Cardiovasc Res, June 1, 2004; 62(3): 450 - 459.
[Abstract] [Full Text] [PDF]

G. M. Felker, R. L. Benza, A. B. Chandler, J. D. Leimberger, M. S. Cuffe, R. M. Califf, M. Gheorghiade, C. M. O'Connor, and OPTIME-CHF Investigators
Heart failure etiology and response tomilrinone in decompensated heart failure: Results from the OPTIME-CHF study
J. Am. Coll. Cardiol., March 19, 2003; 41(6): 997 - 1003.
[Abstract] [Full Text] [PDF]

B. Greenberg, C. Borghi, and S. Perrone
Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?
Eur J Heart Fail, January 1, 2003; 5(1): 13 - 21.
[Abstract] [Full Text] [PDF]

V. V. McLaughlin, A. Shillington, and S. Rich
Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy
Circulation, September 17, 2002; 106(12): 1477 - 1482.
[Abstract] [Full Text] [PDF]

B. D. Lowes, M. Higginbotham, L. Petrovich, M. A. DeWood, M. A. Greenberg, P. S. Rahko, G. W. Dec, T. H. LeJemtel, R. L. Roden, M. M. Schleman, et al.
Low-dose enoximone improves exercise capacity in chronic heart failure
J. Am. Coll. Cardiol., August 1, 2000; 36(2): 501 - 508.
[Abstract] [Full Text] [PDF]

C. Opasich, A. Russo, R. Mingrone, M. Zambelli, and L. Tavazzi
Intravenous inotropic agents in the intensive therapy unit: do they really make a difference?
Eur J Heart Fail, March 1, 2000; 2(1): 7 - 11.
[Abstract] [Full Text] [PDF]

M. A. Movsesian
Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate
J. Am. Coll. Cardiol., August 1, 1999; 34(2): 318 - 324.
[Abstract] [Full Text] [PDF]

A. Iwasaki, A. Matsumori, T. Yamada, T. Shioi, W. Wang, K. Ono, R. Nishio, M. Okada, and S. Sasayama
Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis
J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1400 - 1407.
[Abstract] [Full Text] [PDF]

G. Hasenfuss, B. Pieske, M. Castell, B. Kretschmann, L. S. Maier, and H. Just
Influence of the Novel Inotropic Agent Levosimendan on Isometric Tension and Calcium Cycling in Failing Human Myocardium
Circulation, November 17, 1998; 98(20): 2141 - 2147.
[Abstract] [Full Text] [PDF]

W. T. Abraham
Pharmacologic Management of Chronic Heart Failure: A Review
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190.
[Abstract] [PDF]

K. Eto, K. Hashimoto, and H. Nakaya
Preferential inhibition of IKr by MCI-154, a putative cardiotonic Ca2+ sensitizer, in guinea pig atrial cells
Cardiovasc Res, June 1, 1998; 38(3): 685 - 694.
[Abstract] [Full Text] [PDF]

M. Kitakaze, T. Minamino, H. Funaya, K. Node, Y. Shinozaki, H. Mori, and M. Hori
Vesnarinone Limits Infarct Size via Adenosine-Dependent Mechanisms in the Canine Heart
Circulation, April 15, 1997; 95(8): 2108 - 2114.
[Abstract] [Full Text]

G. Hasenfuss, L. A. Mulieri, P. D. Allen, H. Just, and N.R. Alpert
Influence of Isoproterenol and Ouabain on Excitation-Contraction Coupling, Cross-Bridge Function, and Energetics in Failing Human Myocardium
Circulation, December 15, 1996; 94(12): 3155 - 3160.
[Abstract] [Full Text]

D. A. Lathrop, P. P. Nainasi, A. Varro, and A. Schwartz
Comparison of the Electromechanical Effects of Vesnarinone and Amrinone in Isolated Dog Purkinje Strands and Ventricular Trabeculae
Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 1996; 1(2): 133 - 140.
[Abstract] [PDF]

H. Asanoi, T. Kameyama, S. Ishizaka, T. Nozawa, and H. Inoue
Energetically Optimal Left Ventricular Pressure for the Failing Human Heart
Circulation, January 1, 1996; 93(1): 67 - 73.
[Abstract] [Full Text]

M. Sata, S. Sugiura, H. Yamashita, H. Fujita, S.-i. Momomura, and T. Serizawa
MCI-154 Increases Ca2+ Sensitivity of Reconstituted Thin Filament : A Study Using a Novel In Vitro Motility Assay Technique
Circ. Res., April 1, 1995; 76(4): 626 - 633.
[Abstract] [Full Text]

G. W. Dec and V. Fuster
Idiopathic Dilated Cardiomyopathy
N. Engl. J. Med., December 8, 1994; 331(23): 1564 - 1575.
[Full Text]

H J Dargie and J J V McMurray
Fortnightly Review: Diagnosis and management of heart failure
BMJ, January 29, 1994; 308(6924): 321 - 328.
[Abstract] [Full Text]

K. Swedberg, H. Wedel, D. Neely, A. Schwartz, A. M. Feldman, M. R. Bristow, W. W. Parmley, and M. Packer
Vesnarinone for Heart Failure
N. Engl. J. Med., January 6, 1994; 330(1): 64 - 66.
[Full Text]

A. M. Feldman, M. R. Bristow, W. W. Parmley, P. E. Carson, C. J. Pepine, E. M. Gilbert, J. E. Strobeck, G. H. Hendrix, E. R. Powers, R. P. Bain, et al.
Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure
N. Engl. J. Med., July 15, 1993; 329(3): 149 - 155.
[Abstract] [Full Text]

A. M. Feldman
Can We Alter Survival in Patients With Congestive Heart Failure?
JAMA, April 8, 1992; 267(14): 1956 - 1961.
[Abstract] [PDF]

ENOXIMONE WORSENS SURVIVAL IN HEART FAILURE
Journal Watch (General), September 25, 1990; 1990(925): 6 - 6.
[Full Text]

				J. N. Cohn Inotropic therapy for heart failure: paradise lost Eur. Heart J., December 2, 2009; 30(24): 2965 - 2966. [Full Text] [PDF]

				S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]

				M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, M. A. Silver, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1343 - 1382. [Full Text] [PDF]

				2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA, M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): 1977 - 2016. [Full Text] [PDF]

				2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]

				C. J.F. Holubarsch, W. S. Colucci, T. Meinertz, W. Gaus, M. Tendera, and Survival and Prognosis: Investigation of Crataegus The efficacy and safety of Crataegus extract WS(R) 1442 in patients with heart failure: The SPICE trial Eur J Heart Fail, December 1, 2008; 10(12): 1255 - 1263. [Abstract] [Full Text] [PDF]

				M. Fenton and M. Burch Understanding chronic heart failure Arch. Dis. Child., September 1, 2007; 92(9): 812 - 816. [Abstract] [Full Text] [PDF]

				B. Keweloh, P. M.L. Janssen, U. Siegel, N. Datz, O. Zeitz, and H.-P. Hermann Influence of pyruvate on economy of contraction in isolated rabbit myocardium Eur J Heart Fail, August 1, 2007; 9(8): 754 - 761. [Abstract] [Full Text] [PDF]

				A. L. Taylor, S. Ziesche, C. W. Yancy, P. Carson, K. Ferdinand, M. Taylor, K. Adams, A. Y. Olukotun, E. Ofili, S. W. Tam, et al. Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial Circulation, April 3, 2007; 115(13): 1747 - 1753. [Abstract] [Full Text] [PDF]

				J. G.F. Cleland, A. P. Coletta, M. Lammiman, K. K. Witte, H. Loh, M. Nasir, and A. L. Clark Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE Eur J Heart Fail, October 1, 2005; 7(6): 1070 - 1075. [Abstract] [Full Text] [PDF]

				K. Lalukota, J. G.F. Cleland, L. Ingle, A. L. Clark, and A. P. Coletta Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD Eur J Heart Fail, December 1, 2004; 6(7): 953 - 955. [Abstract] [Full Text] [PDF]

				J. J. Magner and D. Royston Heart failure Br. J. Anaesth., July 1, 2004; 93(1): 74 - 85. [Abstract] [Full Text] [PDF]

				M. A Movsesian Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy Cardiovasc Res, June 1, 2004; 62(3): 450 - 459. [Abstract] [Full Text] [PDF]

				G. M. Felker, R. L. Benza, A. B. Chandler, J. D. Leimberger, M. S. Cuffe, R. M. Califf, M. Gheorghiade, C. M. O'Connor, and OPTIME-CHF Investigators Heart failure etiology and response tomilrinone in decompensated heart failure: Results from the OPTIME-CHF study J. Am. Coll. Cardiol., March 19, 2003; 41(6): 997 - 1003. [Abstract] [Full Text] [PDF]

				B. Greenberg, C. Borghi, and S. Perrone Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan? Eur J Heart Fail, January 1, 2003; 5(1): 13 - 21. [Abstract] [Full Text] [PDF]

				V. V. McLaughlin, A. Shillington, and S. Rich Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy Circulation, September 17, 2002; 106(12): 1477 - 1482. [Abstract] [Full Text] [PDF]

				B. D. Lowes, M. Higginbotham, L. Petrovich, M. A. DeWood, M. A. Greenberg, P. S. Rahko, G. W. Dec, T. H. LeJemtel, R. L. Roden, M. M. Schleman, et al. Low-dose enoximone improves exercise capacity in chronic heart failure J. Am. Coll. Cardiol., August 1, 2000; 36(2): 501 - 508. [Abstract] [Full Text] [PDF]

				C. Opasich, A. Russo, R. Mingrone, M. Zambelli, and L. Tavazzi Intravenous inotropic agents in the intensive therapy unit: do they really make a difference? Eur J Heart Fail, March 1, 2000; 2(1): 7 - 11. [Abstract] [Full Text] [PDF]

				M. A. Movsesian Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate J. Am. Coll. Cardiol., August 1, 1999; 34(2): 318 - 324. [Abstract] [Full Text] [PDF]

				A. Iwasaki, A. Matsumori, T. Yamada, T. Shioi, W. Wang, K. Ono, R. Nishio, M. Okada, and S. Sasayama Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1400 - 1407. [Abstract] [Full Text] [PDF]

				G. Hasenfuss, B. Pieske, M. Castell, B. Kretschmann, L. S. Maier, and H. Just Influence of the Novel Inotropic Agent Levosimendan on Isometric Tension and Calcium Cycling in Failing Human Myocardium Circulation, November 17, 1998; 98(20): 2141 - 2147. [Abstract] [Full Text] [PDF]

				W. T. Abraham Pharmacologic Management of Chronic Heart Failure: A Review Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190. [Abstract] [PDF]

				K. Eto, K. Hashimoto, and H. Nakaya Preferential inhibition of IKr by MCI-154, a putative cardiotonic Ca2+ sensitizer, in guinea pig atrial cells Cardiovasc Res, June 1, 1998; 38(3): 685 - 694. [Abstract] [Full Text] [PDF]

				M. Kitakaze, T. Minamino, H. Funaya, K. Node, Y. Shinozaki, H. Mori, and M. Hori Vesnarinone Limits Infarct Size via Adenosine-Dependent Mechanisms in the Canine Heart Circulation, April 15, 1997; 95(8): 2108 - 2114. [Abstract] [Full Text]

				G. Hasenfuss, L. A. Mulieri, P. D. Allen, H. Just, and N.R. Alpert Influence of Isoproterenol and Ouabain on Excitation-Contraction Coupling, Cross-Bridge Function, and Energetics in Failing Human Myocardium Circulation, December 15, 1996; 94(12): 3155 - 3160. [Abstract] [Full Text]

				D. A. Lathrop, P. P. Nainasi, A. Varro, and A. Schwartz Comparison of the Electromechanical Effects of Vesnarinone and Amrinone in Isolated Dog Purkinje Strands and Ventricular Trabeculae Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 1996; 1(2): 133 - 140. [Abstract] [PDF]

				H. Asanoi, T. Kameyama, S. Ishizaka, T. Nozawa, and H. Inoue Energetically Optimal Left Ventricular Pressure for the Failing Human Heart Circulation, January 1, 1996; 93(1): 67 - 73. [Abstract] [Full Text]

				M. Sata, S. Sugiura, H. Yamashita, H. Fujita, S.-i. Momomura, and T. Serizawa MCI-154 Increases Ca2+ Sensitivity of Reconstituted Thin Filament : A Study Using a Novel In Vitro Motility Assay Technique Circ. Res., April 1, 1995; 76(4): 626 - 633. [Abstract] [Full Text]

				G. W. Dec and V. Fuster Idiopathic Dilated Cardiomyopathy N. Engl. J. Med., December 8, 1994; 331(23): 1564 - 1575. [Full Text]

				H J Dargie and J J V McMurray Fortnightly Review: Diagnosis and management of heart failure BMJ, January 29, 1994; 308(6924): 321 - 328. [Abstract] [Full Text]